Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27876100 | 0.90 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL13740188 | 0.85 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3CHRM4CYP3A4 | |
| SCHEMBL2237131 | 0.81 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3CHRM4CYP3A4 | |
| SCHEMBL2237137 | 0.81 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3CHRM4CYP3A4 | |
| SCHEMBL1920029 | 0.78 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28246290 | 0.77 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3821799 | 0.77 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1221462 | 0.77 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4517836 | 0.76 | SLC6A2 (0.68) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL18704813 | 0.75 | SLC6A2 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | SLC6A4 4238/4885SLC6A2 4321/4885SLC6A3 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.